NRIXNasdaqPharmaceutical PreparationsFiscal year ends November 30
Nurix Therapeutics, Inc.
Financials through Q3 FY2026, quarter ended Aug 31, 2026Last filing: 10-Q on Oct 13, 2026
$24.93+0.51 (+2.09%)
Close on Oct 19, 2026
- Market cap
- $2.90B
- P/E (TTM)
- 10.8
- Dividend yield
- 0.00%
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
100.0%
117M of 104M shares
Institutional holders
211
47 new, 28 sold out
Net institutional buying
0M
In Q2 2026
Insider trades, 12 months
0 buys · 40 sales
Net sold $4.53M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Jeremy C. Green | 8,782,256 | 8.10% | 13G (passive) amendment | Jun 30, 2026 |
| Vestal Point Capital, LP | 8,050,000 | 7.80% | 13G (passive) amendment | Jun 30, 2026 |
| Deep Track Capital, LP | 7,736,455 | 7.45% | 13G (passive) amendment | Jun 30, 2026 |
| Baker Bros. Advisors LP | 7,527,996 | 7.20% | 13G (passive) amendment | Dec 31, 2025 |
| Rubric Capital Management LP | 7,227,778 | 6.96% | 13G (passive) | Jun 30, 2026 |
| David Kroin | 6,345,244 | 6.17% | 13G (passive) amendment | Mar 31, 2026 |
| BlackRock, Inc. | 6,284,116 | 8.20% | 13G (passive) amendment | Mar 31, 2025 |
| Abigail P. Johnson | 5,541,271 | 5.40% | 13G (passive) | Mar 31, 2026 |
| Perceptive Life Sciences Master Fund, Ltd. | 5,536,629 | 5.30% | 13G (passive) | Sep 16, 2026 |
| Deep Track Biotechnology Master Fund, Ltd. | 5,500,000 | 7.21% | 13G (passive) amendment | Mar 31, 2025 |
| T. Rowe Price Associates, Inc. | 5,436,587 | 5.30% | 13G (passive) | Jun 30, 2026 |
| Vanguard Capital Management | 5,202,025 | 5.03% | 13G (passive) | Jun 30, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of NRIX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 8,770,349 | 8.45% | $212.77M | −155,293 | 0.00% |
| Vestal Point Capital, LP | 8,050,000 | 7.76% | $195.29M | +1,550,000 | 4.56% |
| Deep Track Capital, LP | 7,736,455 | 7.45% | $187.69M | +1,391,211 | 2.73% |
| Rubric Capital Management LP | 7,227,778 | 6.96% | $175.35M | +4,753,893 | 1.61% |
| FMR LLC | 5,485,215 | 5.29% | $133.07M | −56,056 | 0.01% |
| Price T Rowe Associates Inc /Md/ | 5,436,587 | 5.24% | $131.89K | +2,146,354 | 0.01% |
| Morgan Stanley | 4,762,484 | 4.59% | $115.54M | −169,515 | 0.01% |
| State Street Corp | 4,677,244 | 4.51% | $113.47M | −463,951 | 0.00% |
| Baker Bros. Advisors LP | 4,658,556 | 4.49% | $113.02M | – | 0.57% |
| Vanguard Capital Management LLC | 4,495,529 | 4.33% | $109.06M | +68,417 | 0.00% |
| Perceptive Advisors LLC | 4,320,422 | 4.16% | $104.81M | +609,545 | 1.57% |
| Redmile Group, LLC | 4,073,787 | 3.93% | $98.83M | −3,659,021 | 6.64% |
| General Atlantic, L.P. | 3,032,185 | 2.92% | $73.56M | −1,069,680 | 2.53% |
| Geode Capital Management, LLC | 2,537,291 | 2.44% | $61.57M | +17,062 | 0.00% |
| Pictet Asset Management Holding SA | 2,351,232 | 2.27% | $57.04M | −374,906 | 0.05% |
| ARK Investment Management LLC | 1,793,196 | 1.73% | $43.50M | +72,061 | 0.28% |
| Capital World Investors | 1,787,916 | 1.72% | $43.37M | +894,589 | 0.01% |
| Trails Edge Capital Partners, LP | 1,573,220 | 1.52% | $38.17M | −170,000 | 6.06% |
| Vanguard Portfolio Management LLC | 1,482,861 | 1.43% | $35.97M | +380,595 | 0.00% |
| Citadel Advisors LLC | 1,477,019 | 1.42% | $35.83M | +133,319 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 211 | 117M | 100.0% | 47 / 67 | 63 / 28 | 18M | 18M |
| Q1 2026 | 196 | 117M | 100.0% | 44 / 67 | 43 / 27 | 20M | 10M |
| Q4 2025 | 182 | 114M | 100.0% | 39 / 93 | 29 / 28 | 43M | 14M |
| Q3 2025 | 173 | 85M | 81.7% | 34 / 50 | 59 / 24 | 9M | 13M |
| Q2 2025 | 163 | 88M | 85.2% | 23 / 68 | 44 / 30 | 13M | 9M |
| Q1 2025 | 170 | 85M | 81.5% | 29 / 66 | 51 / 32 | 11M | 7M |
| Q4 2024 | 175 | 81M | 78.1% | 36 / 66 | 47 / 31 | 21M | 8M |
| Q3 2024 | 172 | 68M | 65.5% | 29 / 65 | 58 / 30 | 16M | 6M |
| Q2 2024 | 174 | 65M | 62.7% | 53 / 62 | 45 / 17 | 21M | 10M |
| Q1 2024 | 139 | 54M | 52.2% | 28 / 42 | 44 / 17 | 10M | 5M |
| Q4 2023 | 130 | 49M | 47.5% | 25 / 46 | 37 / 23 | 11M | 7M |
| Q3 2023 | 128 | 45M | 43.2% | 13 / 41 | 51 / 10 | 4M | 2M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of NRIX | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 3,273,943 | 3.15% | $79.43M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 2,506,930 | 2.42% | $60.82M | 0.07% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 2,459,381 | 2.37% | $59.66M | 0.56% | Jun 30, 2026 |
| SMALLCAP World Fund Inc | 1,739,335 | 1.68% | $42.20M | 0.04% | Jun 30, 2026 |
| ARK Genomic Revolution ETF | 1,682,054 | 1.62% | $39.04M | 2.51% | Jul 31, 2026 |
| Eventide Healthcare & Life Sciences Fund | 1,297,893 | 1.25% | $31.49M | 1.76% | Jun 30, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 1,186,512 | 1.14% | $28.78M | 0.24% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 1,114,472 | 1.07% | $27.04M | 0.03% | Jun 30, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 1,097,649 | 1.06% | $26.63M | 0.18% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 1,047,808 | 1.01% | $24.32M | 0.07% | Jul 31, 2026 |
| Fidelity Small Cap Growth Fund | 948,302 | 0.91% | $22.01M | 0.25% | Jul 31, 2026 |
| T. Rowe Price Integrated U.S. Small-Cap Growth Equity Fund | 942,854 | 0.91% | $22.87M | 0.23% | Jun 30, 2026 |
| iShares Biotechnology ETF | 695,275 | 0.67% | $16.87M | 0.19% | Jun 30, 2026 |
| iShares Russell 2000 Growth ETF | 681,706 | 0.66% | $16.54M | 0.11% | Jun 30, 2026 |
| Fidelity Growth Company Fund | 646,065 | 0.62% | $11.47M | 0.01% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Arthur T. Sands | President, CEO, Director | 608,333 | 0.59% | Feb 10, 2026 |
| Christine Ring | Chief Legal Officer | 9,510 | 0.01% | Sep 2, 2026 |
| Gwenn Hansen | Chief Scientific Officer | 118,679 | 0.11% | Sep 1, 2026 |
| Houte Hans van | Chief Financial Officer | 40,166 | 0.04% | Aug 4, 2026 |
| Paul M. Silva | Director | – | – | May 15, 2026 |
| Anil Kapur | Director | – | – | May 15, 2026 |
| David L. Lacey | Director | 33,333 | 0.03% | May 15, 2026 |
| Roger D. Dansey | Director | – | – | May 15, 2026 |
| Edward C. Saltzman | Director | – | – | May 15, 2026 |
| Roy D. Baynes | Director | – | – | May 15, 2026 |
| Judith A. Reinsdorf | Director | – | – | May 15, 2026 |
| Julia P. Gregory | Director | 10,750 | 0.01% | May 15, 2026 |
| Lori Anne Kunkel | Director | 0 | – | May 19, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Christine Ring Chief Legal Officer | Sep 2, 2026 | Sale(10b5-1 plan) | −5,387 | $25.69 | $138.39K | 9,510 |
| Christine Ring Chief Legal Officer | Sep 2, 2026 | Sale(10b5-1 plan) | −400 | $26.64 | $10.66K | 9,110 |
| Christine Ring Chief Legal Officer | Sep 2, 2026 | Option exercise | +5,787 | $8.72 | $50.46K | 14,897 |
| Gwenn Hansen Chief Scientific Officer | Sep 1, 2026 | Option exercise | +1,452 | $1.86 | $2.70K | 118,679 |
| Gwenn Hansen Chief Scientific Officer | Sep 1, 2026 | Sale(10b5-1 plan) | −1,452 | $25.47 | $36.98K | 117,227 |
| Gwenn Hansen Chief Scientific Officer | Aug 5, 2026 | Option exercise | +4,356 | $1.86 | $8.10K | 121,583 |
| Gwenn Hansen Chief Scientific Officer | Aug 5, 2026 | Sale(10b5-1 plan) | −4,356 | $25.00 | $108.90K | 117,227 |
| Gwenn Hansen Chief Scientific Officer | Aug 4, 2026 | Sale(10b5-1 plan) | −1,500 | $23.87 | $35.81K | 119,838 |
| Gwenn Hansen Chief Scientific Officer | Aug 4, 2026 | Sale(10b5-1 plan) | −2,611 | $24.64 | $64.34K | 117,227 |
| Houte Hans van Chief Financial Officer | Aug 4, 2026 | Sale(10b5-1 plan) | −2,967 | $24.65 | $73.14K | 40,166 |
| Houte Hans van Chief Financial Officer | Aug 4, 2026 | Sale(10b5-1 plan) | −1,794 | $23.89 | $42.86K | 43,133 |
| Christine Ring Chief Legal Officer | Aug 3, 2026 | Option exercise | +5,787 | $8.72 | $50.46K | 25,699 |
| Christine Ring Chief Legal Officer | Aug 3, 2026 | Sale(10b5-1 plan) | −16,589 | $23.05 | $382.38K | 9,110 |
| Christine Ring Chief Legal Officer | Jul 30, 2026 | Sale | −3,847 | $23.38 | $89.94K | 19,912 |
| Christine Ring Chief Legal Officer | Jul 30, 2026 | Option exercise | +3,750 | – | – | 17,329 |
| Christine Ring Chief Legal Officer | Jul 30, 2026 | Option exercise | +2,858 | – | – | 20,187 |
| Christine Ring Chief Legal Officer | Jul 30, 2026 | Option exercise | +3,572 | – | – | 23,759 |
| Houte Hans van Chief Financial Officer | Jul 30, 2026 | Option exercise | +2,858 | – | – | 44,200 |
| Houte Hans van Chief Financial Officer | Jul 30, 2026 | Option exercise | +3,572 | – | – | 47,772 |
| Houte Hans van Chief Financial Officer | Jul 30, 2026 | Sale | −2,845 | $23.38 | $66.52K | 44,927 |
| Houte Hans van Chief Financial Officer | Jul 30, 2026 | Option exercise | +3,750 | – | – | 41,342 |
| Gwenn Hansen Chief Scientific Officer | Jul 30, 2026 | Option exercise | +3,750 | – | – | 118,755 |
| Gwenn Hansen Chief Scientific Officer | Jul 30, 2026 | Option exercise | +2,858 | – | – | 121,613 |
| Gwenn Hansen Chief Scientific Officer | Jul 30, 2026 | Sale | −3,847 | $23.38 | $89.94K | 121,338 |
| Gwenn Hansen Chief Scientific Officer | Jul 30, 2026 | Option exercise | +3,572 | – | – | 125,185 |
| Christine Ring Chief Legal Officer | Jul 2, 2026 | Option exercise | +5,221 | $1.86 | $9.71K | 18,800 |
| Christine Ring Chief Legal Officer | Jul 2, 2026 | Option exercise | +5,787 | $8.72 | $50.46K | 24,587 |
| Christine Ring Chief Legal Officer | Jul 2, 2026 | Sale(10b5-1 plan) | −11,008 | $23.56 | $259.35K | 13,579 |
| Gwenn Hansen Chief Scientific Officer | Jun 25, 2026 | Sale(10b5-1 plan) | −5,394 | $20.00 | $107.88K | 115,005 |
| Christine Ring Chief Legal Officer | Jun 25, 2026 | Option exercise | +13,333 | $7.26 | $96.80K | 26,912 |
| Christine Ring Chief Legal Officer | Jun 25, 2026 | Option exercise | +15,602 | $8.72 | $136.05K | 42,514 |
| Christine Ring Chief Legal Officer | Jun 25, 2026 | Sale(10b5-1 plan) | −28,935 | $20.06 | $580.44K | 13,579 |
| Christine Ring Chief Legal Officer | Jun 2, 2026 | Option exercise | +3,422 | $1.86 | $6.36K | 21,727 |
| Christine Ring Chief Legal Officer | Jun 2, 2026 | Sale(10b5-1 plan) | −8,148 | $16.60 | $135.26K | 13,579 |
| Houte Hans van Chief Financial Officer | May 5, 2026 | Sale(10b5-1 plan) | −13,473 | $16.58 | $223.38K | 38,174 |
| Houte Hans van Chief Financial Officer | May 5, 2026 | Sale(10b5-1 plan) | −582 | $17.18 | $10.00K | 37,592 |
| Christine Ring Chief Legal Officer | May 4, 2026 | Sale(10b5-1 plan) | −8,148 | $16.96 | $138.19K | 18,305 |
| Christine Ring Chief Legal Officer | May 1, 2026 | Sale(10b5-1 plan) | −5,394 | $16.76 | $90.40K | 26,453 |
| Christine Ring Chief Legal Officer | Apr 30, 2026 | Sale | −3,214 | $16.65 | $53.51K | 31,847 |
| Christine Ring Chief Legal Officer | Apr 30, 2026 | Option exercise | +2,858 | – | – | 35,061 |
| Christine Ring Chief Legal Officer | Apr 30, 2026 | Option exercise | +3,750 | – | – | 32,203 |
| Christine Ring Chief Legal Officer | Apr 30, 2026 | Option exercise | +2,000 | – | – | 28,453 |
| Houte Hans van Chief Financial Officer | Apr 30, 2026 | Option exercise | +3,750 | – | – | 51,177 |
| Houte Hans van Chief Financial Officer | Apr 30, 2026 | Option exercise | +2,000 | – | – | 47,427 |
| Houte Hans van Chief Financial Officer | Apr 30, 2026 | Option exercise | +2,858 | – | – | 54,035 |
| Houte Hans van Chief Financial Officer | Apr 30, 2026 | Sale | −2,388 | $16.65 | $39.76K | 51,647 |
| Gwenn Hansen Chief Scientific Officer | Apr 30, 2026 | Option exercise | +3,750 | – | – | 120,755 |
| Gwenn Hansen Chief Scientific Officer | Apr 30, 2026 | Option exercise | +2,000 | – | – | 117,005 |
| Gwenn Hansen Chief Scientific Officer | Apr 30, 2026 | Option exercise | +2,858 | – | – | 123,613 |
| Gwenn Hansen Chief Scientific Officer | Apr 30, 2026 | Sale | −3,214 | $16.65 | $53.51K | 120,399 |
| Christine Ring Chief Legal Officer | Apr 2, 2026 | Sale(10b5-1 plan) | −8,148 | $15.24 | $124.18K | 26,453 |
| Christine Ring Chief Legal Officer | Mar 2, 2026 | Sale(10b5-1 plan) | −8,148 | $15.44 | $125.81K | 34,601 |
| Christine Ring Chief Legal Officer | Feb 9, 2026 | Sale(10b5-1 plan) | −14,261 | $16.66 | $237.59K | 42,749 |
| Gwenn Hansen Chief Scientific Officer | Feb 3, 2026 | Option exercise | +31,333 | $0.84 | $26.32K | 115,005 |
| Gwenn Hansen Chief Scientific Officer | Jan 30, 2026 | Option exercise | +3,750 | – | – | 85,708 |
| Gwenn Hansen Chief Scientific Officer | Jan 30, 2026 | Sale | −4,797 | $16.58 | $79.53K | 83,770 |
| Gwenn Hansen Chief Scientific Officer | Jan 30, 2026 | Option exercise | +2,859 | – | – | 88,567 |
| Gwenn Hansen Chief Scientific Officer | Jan 30, 2026 | Sale | −98 | $17.37 | $1.70K | 83,672 |
| Gwenn Hansen Chief Scientific Officer | Jan 30, 2026 | Option exercise | +2,000 | – | – | 81,958 |
| Gwenn Hansen Chief Scientific Officer | Jan 30, 2026 | Option exercise | +3,207 | – | – | 79,958 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Gregory Julia Director | Oct 14, 2026 | 22,583 | $528.53K | Oct 14, 2026 | Stock Option Exercise |
| Ring Christine Officer | Oct 2, 2026 | 5,786 | $135.05K | Oct 2, 2026 | Exercise of Stock Options |
| Ring Christine Officer | Sep 2, 2026 | 5,787 | $150.69K | Sep 2, 2026 | Exercise of Stock Options |
| Hansen Gwenn Officer | Aug 5, 2026 | 8,712 | $215.10K | Aug 5, 2026 | Exercise of Stock Options |
| Van Houte Johannes Officer | Aug 4, 2026 | 4,761 | $110.55K | Aug 4, 2026 | Restricted Stock Units |
| M. Hansen Gwenn Officer | Aug 4, 2026 | 4,111 | $95.46K | Aug 4, 2026 | Restricted Stock Units |
| Ring Christine Officer | Aug 3, 2026 | 16,589 | $385.03K | Aug 3, 2026 | Exercise of Stock Options |
| Ring Christine Officer | Jul 2, 2026 | 11,008 | $263.20K | Jul 2, 2026 | Exercise of Stock Options |
| Ring Christine Officer | Jun 25, 2026 | 28,935 | $558.45K | Jun 25, 2026 | Exercise of Stock Options |
| M. Hansen Gwenn Officer | Jun 25, 2026 | 5,394 | $104.10K | Jun 25, 2026 | Restricted Stock Units |
| Ring Christine Officer | Jun 2, 2026 | 8,148 | $141.69K | Jun 2, 2026 | Restricted Stock Units |
| Van Houte Johannes Officer | May 5, 2026 | 14,055 | $237.95K | May 5, 2026 | Restricted Stock Units |
| Ring Christine Officer | May 4, 2026 | 8,148 | $136.97K | May 4, 2026 | Restricted Stock Units |
| Ring Christine Officer | May 1, 2026 | 5,394 | $90.08K | May 1, 2026 | Restricted Stock Units |
| Ring Christine Officer | Apr 2, 2026 | 8,148 | $126.13K | Apr 2, 2026 | Restricted Stock Units |